Endologix — Debt Investor Presentation (February 2020)
14 slides from Endologix's debt investor presentation, Feb 24, 2020

Slide 1: Debt Restructuring Supplemental Presentation
February 24, 2020 Debt Restructuring Supplemental Presentation 8 46 97 232 75 55 201 222 251 Exhibit 99.2

Slide 2: Safe Harbor
SAFE HARBOR About this Presentation This presentation (together with any accompanying oral or written communications, this “Presentation”) is being provided in connection with the debt restructuring (the “debt restructuring”) of Endologix, Inc. (“Endologix”). This Presentation is for informational p

Slide 3: Disclosures
DISCLOSURES Endologix products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specific indications, contraindications,

Slide 4: Executive Summary
EXECUTIVE SUMMARY 50% of 2021 amortization payment ($10.8M) equitized and remainder redistributed to remaining two payments(2). April 2020 interest in PIK and subsequent interest paid in equity for 18 months. April 2022 and 2023 payments extended to April and December 2023, respectively. Additional

Slide 5: Transaction Summary
TRANSACTION SUMMARY Endologix, Inc. (“ELGX” or the “Company”) has signed transaction agreements in connection with a recapitalization transaction that addresses the 2020-2023 maturities / amortization payments, provides a clear path to cash flow breakeven in 2021, and allows for substantial delevera

Slide 6: Conditions Precedent
CONDITIONS PRECEDENT The following conditions precedent must be met (the “Conditions Precedent”): 98.7% of 2020 Notes exchanged into the Second Lien Notes(1). $1M of Alto sales within the earlier of i) 3 months of approval or ii) 6/30/20. Upon meeting the Conditions Precedent the Company will receiv

Slide 7: Current and Future Equitization
CURRENT AND FUTURE EQUITIZATION Equity conversions will be satisfied in shares of common stock or shares of convertible non-voting preferred equity. New preferred equity does not have any associated interest rate or dividend and has de minimis liquidation preference. Preferred equity convertible at

Slide 8: 2020 and 2021 Relief Summary
2020 AND 2021 RELIEF SUMMARY All conversions are subject to conversion price exceeding $0.8282. If share price is below $0.8282, the interest payments will revert to current cash / PIK combination. Figure excludes additional PIK interest that would have accrued from Conditions Precedent effective da

Slide 9: 2022 and 2023 Relief Summary
2022 AND 2023 RELIEF SUMMARY Subject to the Conditions Precedent, April 2021 amortization 50% equitized with remaining balance split between two remaining payments. If the Conditions Precedent are not met, the 2021 amortization payment will be July 1, 2021. Illustrative Amortization Schedule Summary

Slide 10: Maturity / Amortization Relief
MATURITY / AMORTIZATION RELIEF Note: Deerfield amortization payments exclude impact from PIK. December 31, 2019 February 24, 2020 ~$100M of 2020 - 2022 maturities extended / equitized with up to ~$90.8M in deleveraging (In Millions) (In Millions)

Slide 11: Endologix Debt Stack Path to Up to ~$90.8M of Potential Debt Reduction
ENDOLOGIX DEBT STACK PATH TO UP TO ~$90.8M(2) OF POTENTIAL DEBT REDUCTION Illustrative Pro Forma Debt(1) $10.8M equitized upon satisfaction of conditions precedent, representing 50% of the previously scheduled 2021 amortization payment. Up to $60M of voluntary / mandatory conversions(3). Up to $20M

Slide 12: Potential Deleveraging Details
POTENTIAL DELEVERAGING DETAILS 2021 Mandatory Amortization Nellix- Linked Forced / Voluntary Conversion 50% of the scheduled April 2021 amortization payment on the First Out Loan will be converted to preferred equity upon satisfaction of the Conditions Precedent. Remaining 50% of the payment will be

Slide 13: Deerfield Facility Financial Covenants
DEERFIELD FACILITY FINANCIAL COVENANTS Financial Covenant Amount TTM Minimum Net Revenue $129M Quarterly Minimum Net Revenue $27M Minimum Global Excess Liquidity $17.5M Maximum Capital Expenditures 2020: $5M / 2021: $2M Fixed Charged Coverage Ratio (Commencing on Trigger Date) Less than 1.00 to 1.00

Slide 14: Endologix
_A Endologix
Source: SEC EDGAR · 8-K filed Feb 24, 2020

